Prescription Drugs

This study of national retail pharmacy data from 2013 to 2022, found an overall increase in buprenorphine dispensed to women of reproductive age and a marked increase in fills that were prescribed by nurse practitioners/physician assistants.

The Inflation Reduction Act established a limit on out-of-pocket spending (“the 2024 cap”) for enrollees with very high prescription drug spending in Medicare Part D, for the first time in the history of the program.

It is anticipated that extreme weather events due to climate change will increase the prevalence of a number of acute and chronic diseases. As a result, the demand for drugs to prevent or treat those conditions is likely to increase.

This landing page presents the abstract of a paper published in Health Affairs. The full text of the article is available at: https://www.healthaffairs.org/doi/abs/10.1377/hlthaff.2023.00837.

The Inflation Reduction Act (IRA) makes improvements to Medicare to increase accessibility and affordability of prescription drugs for Medicare enrollees, reduce the rate of growth in Medicare drug spending, and improve the financial sustainability of the Medicare program.

This ASPE data point links manufacturer location data with the Federal Emergency Management Agency (FEMA) National Risk Index (NRI), which describes relative risk of experiencing a variety of natural hazards in order to highlight the ways in which natural disasters may pose supply chain vulnerabilities within the U.S.

Medical product shortages are an ongoing public health concern, with at least 140 products in shortage as of July 2024.We use the Household Pulse Survey to examine how many adults are affected by shortages of critical medical products in the United States.In fall 2023, shortages of medical products impacted about 38.8 million (18 percent) of individuals in the United Stat

We report findings of a case study of Civica Rx, a U.S. nonprofit pharmaceutical company whose model is based on long-term hospital membership agreements with minimum volume commitments and buffer stock requirements.Related Products:

We report findings of a study that described the emerging nonprofit pharmaceutical industry and its commercialization activities to enhance access to affordable and essential drugs, or resiliency in the supply chains of medical products.

This landing page represents the abstract of a paper published in JAMA. The full text of the article is available at: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2820562.Abstract